Trials / Completed
CompletedNCT01453504
Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma
A Prospective, Randomized, Placebo-controlled, Multicenter, International Phase I/II Trial of RAD001 (Everolimus) in Combination With DHAP as Induction Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 73 (actual)
- Sponsor
- University of Cologne · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is 1. to determine the recommended dose of everolimus for a subsequent Phase II trial 2. to determine the efficacy of everolimus plus DHAP
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DHAP | Dexamethasone, Cytarabine, Cisplatin |
| DRUG | Everolimus |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2019-03-01
- Completion
- 2019-03-01
- First posted
- 2011-10-18
- Last updated
- 2019-11-08
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01453504. Inclusion in this directory is not an endorsement.